Malvern-based TELA Bio® Announces Plans to Launch OviTex® Reinforced BioScaffolds in Europe

Malvern-based TELA Bio® Announces Plans to Launch OviTex® Reinforced BioScaffolds in Europe

MALVERN, PA — TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that its partner Aroa Biosurgery, a soft-tissue repair company based in New Zealand that develops and manufactures medical products to improve healing, has been granted EC Certification (CE Mark) allowing for the commercial launch of OviTex RBSs in the European Union (EU).

“We are excited to announce that our strategic partner has received a CE Mark for OviTex RBSs and look forward to bringing the benefits of this innovative solution to the European market,” said Antony Koblish, president and CEO of TELA Bio. “Historically, biologic products have had limited success in Europe due to their high price points, but our unique supply chain enables us to deliver OviTex RBSs at a significant cost reduction that is well-suited for the healthcare landscape overseas.”

READ:  FDA Approves First Treatment for a Form of Bladder Dysfunction in Pediatric Patients as Young as 2 Years of Age

“Securing EC Certification will provide the opportunity for patients with complex hernia in Europe to gain access to the advantages of OviTex RBSs,” said Brian Ward, CEO of Aroa Biosurgery. “We are pleased that TELA Bio can now build on their growing success in the United States and begin a commercial rollout in Europe.”

TELA Bio first commercialized OviTex RBSs in the U.S. for ventral hernia repairs and abdominal wall reconstruction procedures in July 2016. They are a distinct class of surgical implants that integrate biologic and synthetic materials in a uniquely embroidered construction that allows movement of fluid and cells through the construct. The biologic material, derived from ovine rumen, allows for functional tissue remodeling, while the polymer provides additional strength and improved handling.

More than 2000 implantations with OviTex RBSs have been completed to date in a wide range of hernia procedures using a variety of surgical techniques. Data from a retrospective study presented at the Americas Hernia Society International Hernia Congress 2018 showed the use of OviTex RBSs in abdominal wall reconstruction procedures led to low recurrence and complication rates.i TELA Bio has initiated a post-market clinical study, BioScaffold Reconstruction of Abdominal wall and Ventral hernia defects with Open or laparoscopic repair (BRAVO), to further evaluate the safety and efficacy of OviTex RBSs.

READ:  FDA Approves First Treatment for a Form of Bladder Dysfunction in Pediatric Patients as Young as 2 Years of Age

Source: TELA Bio, Inc., 1 Great Valley Pkwy Ste 24, Malvern PA 19355
i Presented at Americas Hernia Society (AHS) International Hernia Congress 2018, “Abdominal Wall Reconstruction with a New Ovine Polymer-Reinforced Bioscaffold: Early Clinical Experience.”

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee